Endocrine Abstracts

GLP-1 is one of the two known incretin hormones (the other one being GIP), which have the ability to stimulate insulin secretion whenever glucose concentrations are above a certain permissive threshold. The incretin effect (greater stimulation of insulin secretory responses with oral as compared to matched intravenous glucose administration) is reduced in patients with type 2 diabetes, thus the question needed to be addressed, whether there is hyposecretion or impaired action ...

Gastric inhibitory polypeptide (GIP) is a physiologically important incretin hormone secreted from K cell of the upper small intestine. Glucagon-like peptide 1 (GLP-1) is secreted from L cells in the lower small and large intestine. Both hormones are released after nutrient (especially carbohydrate and fat) ingestion and glucose-dependently augment insulin secretion. An involvement of either incretin hormone in the pathogenesis of diabetes may, in principle, be related to abno...

Aims: We investigate the influence of GIP on ghrelin secretion in normal glucose tolerant individuals with the use of the firstly applied correlation network analysis on human plasma metabolome data.Methods: To address this issue, we employed a GIP-infusion test and euglycemic- and hyperglycemic glucose clamp experiments combined with infusion of GIP or placebo in a cross-over manner in non diabetic obese male subjects (n=14). Moreover, we firstly...